The global Lymphoma treatment market is anticipated to grow at a CAGR of around 8% during the forecast period. The Lymphoma treatment industry is gaining traction rapidly with the increasing awareness regarding various therapies available in the market. Since the last decades, there have been a lot of changes in the treatment of lymphoma. Changing from relying on large field high doses of radiation therapy to a combination of chemotherapy and a little bit of some treatment and in some cases just chemotherapy.
Nowadays, most patients who are diagnosed with lymphoma are treated with chemotherapy which can be given by vein or by mouth. There are other patients with lymphoma whose disease is growing slowly and causing so few symptoms that it really can be carefully watched and not treated immediately in contradistinction to the patients with rapidly growing. Lymphomas are oftentimes treated with aggressive high-dose chemotherapy on a very frequent intense schedule to eliminate that lymphoma and cure that patient’s cancer.
Browse the full report description of "Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin and Non-Hodgkin), By Therapy Type (Radiation therapy, Chemotherapy, and Others), By Drug Type (Adcetris, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, and Others), Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/lymphoma-treatment-market
Additionally, certain lymphomas can benefit from the addition of treatment with radiation and that radiation is generally given by the radiation oncologist following a schedule for a prescribed number of weeks of treatment. The combination of chemotherapy radiation can often be Curative for patients with early-stage lymphoma. However, for patients with advanced lymphoma generally, chemotherapy plus or minus radiation can be given. So, the lymphoma treatment market is significantly affected by the rising use of chemotherapy and a combination of various other therapies.
However, there are some long-term side effects of these potential chemotherapies. For instance, an ABVD (adriamycin bleomycin vinblastine dacarbazine) chemotherapy regimen that is used in the first-line treatment of Hodgkin lymphoma contains many side effects. Adriamycin has some toxiceffects on the heart as it can affect the function of heart muscles and that's why patients get evaluated before starting chemotherapy to make sure that they had good heart function. The bleomycin can cause lung toxicity in some patients.
Other side effects may include a small risk of peripheral neuropathy, affecting the peripheral nerves, causing numbness tingling with some constipation nausea, and vomiting. Although, even with these associated side effects, the adoption of chemotherapy is rising anyway fuelling the lymphoma treatment market during the forecast period.
Few Key Findings in the Report
Global Lymphoma Treatment Market- Segmentation
By Type
By Therapy Type
By Drug Type
Global Lymphoma Treatment Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World